About lexicon pharmaceuticals - LXRX
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
LXRX At a Glance
Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Boulevard
The Woodlands, Texas 77381-1160
| Phone | 1-281-863-3000 | Revenue | 31.08M | |
| Industry | Pharmaceuticals: Major | Net Income | -200,403,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 2,481.478% | |
| Fiscal Year-end | 12 / 2025 | Employees | 103 | |
| View SEC Filings |
LXRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.604 |
| Price to Book Ratio | 1.829 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.567 |
| Enterprise Value to Sales | 3.361 |
| Total Debt to Enterprise Value | 1.015 |
LXRX Efficiency
| Revenue/Employee | 301,757.282 |
| Income Per Employee | -1,945,660.194 |
| Receivables Turnover | 8.949 |
| Total Asset Turnover | 0.118 |
LXRX Liquidity
| Current Ratio | 5.441 |
| Quick Ratio | 5.436 |
| Cash Ratio | 5.259 |
LXRX Profitability
| Gross Margin | 96.30 |
| Operating Margin | -594.63 |
| Pretax Margin | -644.777 |
| Net Margin | -644.777 |
| Return on Assets | -75.932 |
| Return on Equity | -167.659 |
| Return on Total Capital | -79.518 |
| Return on Invested Capital | -89.32 |
LXRX Capital Structure
| Total Debt to Total Equity | 72.678 |
| Total Debt to Total Capital | 42.089 |
| Total Debt to Total Assets | 35.545 |
| Long-Term Debt to Equity | 71.873 |
| Long-Term Debt to Total Capital | 41.622 |